Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04120896 | Karate or Kung Fu? | unknown | N/A | 52 | The University of Hong KongOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT04096846 | Effect of Vitamin D Diffiency on Oral Mucosa in Patients Recieving Methotrexate Chemotherapy(VitDandMTX) | unknown | — | 100 | Assiut UniversityOTHER | 0 | Sep 20, 2019 | clinicaltrials |
| NCT04087967 |
| Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients |
| unknown |
| Phase 3 |
| 162 |
| The First Affiliated Hospital of Soochow UniversityOTHER |
| 1 |
| Sep 12, 2019 |
| clinicaltrials |
| NCT04083911 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | unknown | Phase 3 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT04084327 | Immunophenotyping of Acute b Cell Lymphoblstic Leukemia | unknown | — | 50 | South Egypt Cancer InstituteOTHER | 0 | Sep 10, 2019 | clinicaltrials |
| NCT03181815 | Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03318419 | Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01987297 | Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | unknown | Phase 4 | 738 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT04060485 | Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results | unknown | — | 1,000 | National Taiwan University HospitalOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT04007978 | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008251 | Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 | 10 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008381 | Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia | unknown | Phase 1 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04024241 | Medium Dose of Cytarabine and Mitoxantrone(HAM) | unknown | — | 250 | Shenzhen People's HospitalOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04015024 | A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04012879 | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia | unknown | Phase 1 | 12 | Chinese PLA General HospitalOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT03337568 | Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission(AML_AlloHCT) | unknown | — | 110 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03885076 | Gamma Delta T Cells in AML | unknown | — | 20 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT02965092 | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 80 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03366350 | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 50 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03920813 | Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy | unknown | Phase 4 | 500 | Shandong UniversityOTHER | 0 | Apr 23, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02670564 | ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) | unknown | Phase 4 | 1,000 | Swiss Pediatric Oncology GroupOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02861209 | Collaborative Network to Take Responsibility for Oral Anticancer Therapy(CONTACT) | unknown | N/A | 228 | KU LeuvenOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03902197 | CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients | unknown | Phase 2 | 50 | Xuanwu Hospital, BeijingOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03902769 | Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.(AML) | unknown | N/A | 160 | Rambam Health Care CampusOTHER | 0 | Apr 8, 2019 | clinicaltrials |
| NCT03889951 | Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy | unknown | — | 50 | Assiut UniversityOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT03364257 | iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients(IDENTIFY) | unknown | — | 97 | PathoquestINDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT02344966 | Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia | unknown | — | 1,100 | Yonsei UniversityOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT03854994 | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Yan'an Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03000335 | Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk | unknown | — | 65 | Curewize Health Ltd.INDUSTRY | 1 | Feb 4, 2019 | clinicaltrials |
| NCT03825731 | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 20 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03796390 | Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia | unknown | Phase 1 | 15 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03366324 | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT03743909 | Expression of Aberrant CD Markers in Acute Leukemia:Retrospective Study in South Egypt Cancer Institute | unknown | — | 100 | Assiut UniversityOTHER | 0 | Nov 16, 2018 | clinicaltrials |
| NCT03454984 | SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation | unknown | Phase 2 | 40 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00439920 | GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL. | unknown | Phase 2 | — | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Oct 23, 2018 | clinicaltrials |
| NCT03715621 | Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT | unknown | — | 500 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)(TRANSATRA) | unknown | Phase 1 / Phase 2 | 60 | Michael LuebbertOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02933333 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | unknown | Phase 4 | 405 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03665480 | The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03701217 | Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML | unknown | Phase 2 / Phase 3 | 220 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03671460 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 | 18 | Tianjin Mycure Medical Technology Co., LtdINDUSTRY | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03613428 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | unknown | Phase 1 / Phase 2 | 12 | Sichuan UniversityOTHER | 0 | Aug 3, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 9, 2019source: clinicaltrials